长链非编码RNA与雌激素受体阳性乳腺癌患者他莫昔芬耐药关系的研究进展  

Research progress on the relationship between long non-coding Rnas and ta moxifen resistance in estrogen receptor-positive breast cancer patients

作　　者：辛钰 姜慧慧 武洪远 孙成铭[3] XIN Yu;JIANG Huihui;Wu Hongyuan;SUN Chengming(Binzhou Medical College,Yantai 264000,Shandong,China;Qingdao University,Qingdao 266000,China;Department of C linical Laboratory,Yuhuangding Hospital,Yantai 264000,Shandong,China)

机构地区：[1]滨州医学院,山东烟台264000 [2]青岛大学,山东青岛266000 [3]烟台毓璜顶医院检验科,山东烟台264000

出　　处：《当代医药论丛》2022年第4期8-12,共5页

基　　金：山东省烟台市科技计划项目(2019MSGY133)。

摘　　要：现阶段,乳腺癌已成为全球范围内常见的癌症之一。约有75%的乳腺癌患者雌激素受体(ER)呈阳性表达。目前临床上多采用雌激素受体拮抗剂(如他莫昔芬)对ER阳性乳腺癌患者进行治疗。他莫昔芬耐药(TAMR)现象的出现是临床上对此类乳腺癌患者进行治疗的主要障碍。大量的研究表明,长链非编码RNA(lncRNA)与ER阳性乳腺癌患者TAMR之间存在显著的相关性。因此,可将lncRNA作为乳腺癌的生物标志物或治疗的潜在靶点加以研究。本文对近5年来关于lncRNA与ER阳性乳腺癌患者TAMR关系的研究进展进行综述。At present,breast cancer has become one of the most common cancers in the world.About 75%of breast cancer patients are estrogen receptor(ER)positive.At present,estrogen receptor antagonists(such as tamoxifen)are used to treat ER positive breast cancer patients.Tamoxifen resistance(TAMR)is a major obstacle to the clinical treatment of breast cancer patients.A large number of studies have shown a significant correlation between long non-coding RNA(lncRNA)and TAMR in ER positive breast cancer patients.Therefore,lncRNA can be studied as biomarkers or potential therapeutic targets for breast cancer.This article reviews the research progress on the relationship between lncRNA and TAMR in ER positive breast cancer patients in recent 5 years.

关 键 词：长链非编码RNA 雌激素受体 乳腺癌 他莫昔芬 耐药 雌激素受体拮抗剂 

分 类 号：R737.9[医药卫生—肿瘤]